Ignacio Rivero Berti
Ignacio Rivero Berti has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Guillermo Raul Castro
Nanomedicine Research Unit (Nanomed), Center for Natural and Human Sciences (CCNH), Federal University of ABC (UFABC), Santo André, Brazil
3 shared publications - Boris Rodenak-Kladniew
INIBIOLP—Instituto de Investigaciones Bioquímicas de La Plata (UNLP-CONICET LA PLATA), Facultad de Ciencias Médicas UNLP, La Plata 1900, Argentina
2 shared publications - Adrián Alejandro Pérez Rubin
Área de Biocoloides y Nanotecnología, Instituto de Tecnología de Alimentos, Facultad de Ingeniería Química Universidad Nacional del Litoral Santa Fe Argentina
1 shared publication Alejandro Miñan
Instituto de Investigaciones Fisicoquímicas Teóricas y Aplicadas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Casilla de Correo 16, Sucursal 4, 1900 La Plata Argentina
1 shared publicationAna M. Gagneten
Ciudad Universitaria, Universidad Nacional Del Litoral
1 shared publicationBernardo Bayón
Universidad Nacional de La Plata—CONICET (CCT La Plata)
1 shared publication
Latest Publications
- Open Access
- 10 August 2020
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 10 (49) , 29336-29346
Assessment of in vitro cytotoxicity of imidazole ionic liquids and inclusion in targeted drug carriers containing violacein
Violacein (Viol) is a pigment produced by several Gram-negative bacteria with many bioactivities, such as anticancer, virucide, and antiparasitic. However, violacein is insoluble under physiological conditions preventing its potential therapeutic uses. Surface-active ionic liquids (SAILs) based on the cation 1-alkylimidazolium ([CnHim]) with n = 10 to 16 alkyl carbon side chain lengths and acetate, bromide, methanesulfonate (S) or trifluoroacetate (F) as counterions were synthesized and screened to dissolve Viol in micellar aqueous media and for toxicological studies on the human lung carcinoma A549 cell line. Screening allowed the selection of 1.5 × 10−3% (w/v) [C16Him]-S because it combines low cytotoxicity with 71.5% cell viability and good interaction with 95.2% of the violacein kept in micellar solution for at least 48 h. [Viol-([C16Him]-S)] complex was used to develop an efficient hybrid solid lipid nanoparticle (SLN) carrier based on myristyl myristate and poloxamer 188 and tailored with folate to target cancer cells. Cellular SLN uptake was evaluated with fluorescent DiOC18 on A549, HCT-116, and HeLa cell lines expressing or not the folate receptor. The results showed fivefold incorporation of Viol nanoparticles in HCT-116 and HeLa cell cultures, displaying a high level of folate receptor. Biophysical characterization of the hybrid solid lipid carrier containing Viol was performed by dynamic light scattering, Fourier transform infrared, X-ray diffraction and X-ray photoelectron spectroscopies, and by transmission electron and cryo-transmission microscopies.
- 10 August 2020
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 10 (49) , 29336-29346
Open AccessAssessment of in vitro cytotoxicity of imidazole ionic liquids and inclusion in targeted drug carriers containing violacein
Violacein (Viol) is a pigment produced by several Gram-negative bacteria with many bioactivities, such as anticancer, virucide, and antiparasitic. However, violacein is insoluble under physiological conditions preventing its potential therapeutic uses. Surface-active ionic liquids (SAILs) based on the cation 1-alkylimidazolium ([CnHim]) with n = 10 to 16 alkyl carbon side chain lengths and acetate, bromide, methanesulfonate (S) or trifluoroacetate (F) as counterions were synthesized and screened to dissolve Viol in micellar aqueous media and for toxicological studies on the human lung carcinoma A549 cell line. Screening allowed the selection of 1.5 × 10−3% (w/v) [C16Him]-S because it combines low cytotoxicity with 71.5% cell viability and good interaction with 95.2% of the violacein kept in micellar solution for at least 48 h. [Viol-([C16Him]-S)] complex was used to develop an efficient hybrid solid lipid nanoparticle (SLN) carrier based on myristyl myristate and poloxamer 188 and tailored with folate to target cancer cells. Cellular SLN uptake was evaluated with fluorescent DiOC18 on A549, HCT-116, and HeLa cell lines expressing or not the folate receptor. The results showed fivefold incorporation of Viol nanoparticles in HCT-116 and HeLa cell cultures, displaying a high level of folate receptor. Biophysical characterization of the hybrid solid lipid carrier containing Viol was performed by dynamic light scattering, Fourier transform infrared, X-ray diffraction and X-ray photoelectron spectroscopies, and by transmission electron and cryo-transmission microscopies.
- 1 March 2019
- Published by Elsevier in Reactive and Functional Polymers
- Vol. 136, 122-130
Development of biocarrier for violacein controlled release in the treatment of cancer
- 1 March 2019
- Published by Elsevier in Reactive and Functional Polymers
- Vol. 136, 122-130
Development of biocarrier for violacein controlled release in the treatment of cancer
- 8 December 2017
- Published by Springer Nature
- p. 1-44
Biopolymers from Wastes to High-Value Products in Biomedicine
- 8 December 2017
- Published by Springer Nature
- p. 1-44
Biopolymers from Wastes to High-Value Products in Biomedicine
- 1 June 2016
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 142, 214-222
Delivery of fluorophores by calcium phosphate-coated nanoliposomes and interaction with Staphylococcus aureus biofilms
- 1 June 2016
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 142, 214-222
Delivery of fluorophores by calcium phosphate-coated nanoliposomes and interaction with Staphylococcus aureus biofilms